Image may be NSFW.
Clik here to view.
Allergan (NYSE:AGN) and the St. Regis Mohawk Tribe asked the Federal Circuit last week to stop the U.S. Patent Trial and Appeal Board from reviewing the IP for Allergan’s blockbuster eye drug, Restasis.
The move comes in response to the board’s February decision that sovereign immunity does not shield tribes from patent challenges.
Get the full story at our sister site, Drug Delivery Business News.
The post Tribe looks to stop patent board’s review of Restasis IP appeared first on MassDevice.
